INTRODUCTION
Saprophytic and commensal fungi infect billions of people each year [1, 2] . Medically important fungi include yeast Candida spp., mold Aspergillus spp., the atypical fungus Pneumocystis jirovecii, dimorphic (Coccidioides, Paracoccidioides and Histoplasmosma spp.) fungi, dermatophytes (e.g. Trichophyton spp.) and encapsulated yeast Cryptococcus spp. Invasive fungal diseases (IFDs), such as candidiasis, aspergillosis, pneumocystosis and cryptococcosis in particular, have become a major health problem [3, 4] . The acquired immunodeficiency syndrome (AIDS) epidemic, the more widespread use of immunosuppressive therapies, the longer survival of immunosuppressed patients, the increased use of intravenous lines and the increased movements of patients at risk are the main acquired risk factors contributing to IFDs. Despite advances in treatment, mortality rates for IFDs remain high, at 30-50% [5] [6] [7] . Superficial fungal diseases, although less severe, can also lead to significant morbidity [8] .
In any case, a number of superficial and invasive fungal infections are not explained by any of the known risk factors.
It is important to understand the pathogenesis of fungal infections in patients without known risk factors. It is also timely to decipher the cellular and molecular mechanisms of antifungal immunity, with a view to developing new tools for treating fungal infections [7, 9] and new preventive measures, including vaccines [10] . The study of primary immunodeficiencies (PIDs) conferring a predisposition to fungal infections can serve both purposes, as the elucidation of genetic etiologies of unexplained fungal diseases also improves our understanding of antifungal immunity in other settings [11] [12] [13] [14] . In recent years, the genetic dissection of chronic mucocutaneous candidiasis disease (CMCD) has revealed a role for interleukins-17 in mucocutaneous immunity to C. albicans [7, 15, 16 & , 17,18 & ]. Other examples include the role played by caspase recruitment domain-containing protein 9 (CARD9) in IFDs caused by dermatophytes and Candida spp., that of interferon (IFN)-g in immunity to dimorphic fungi, and that of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex in immunity to Aspergillus spp. We review here the PIDs known to confer a predisposition to fungal infections.
PRIMARY IMMUNODEFICIENCIES UNDERLYING CHRONIC MUCOCUTANEOUS CANDIDIASIS
Candida spp. are cosmopolite commensal yeasts colonizing the skin (C. parapsilosis) and digestive tract (C. albicans) of healthy individuals. However, they can lead to superficial mucocutaneous infections, which can occasionally become chronic (chronic mucocutaneous candidiasis or CMC). CMC is characterized by persistent or recurrent infections of the mouth, esophagus, digestive and genital mucosae, nails and/or skin, mostly with C. albicans. CMC is frequent, and associated with other infections caused by a broad spectrum of microorganisms, in the context of acquired conditions (HIV infection, immunosuppressive therapies, prolonged antibiotic therapies, diabetes mellitus) or various inherited primary T-cell immunodeficiencies. Patients with severe combined immunodeficiencies (SCID) and patients with combined immunodeficiencies (CID) develop CMC in infancy because of T-cell deficiency [16
Patients with idiopathic CD4 lymphopenia are also susceptible to CMC. All known patients with an autosomal dominant IkBa gain-of-function (GOF) mutation [19, 20] and impaired nuclear factor-kB (NF-kB) signaling have developed CMC and other fungal infections [19] . Two-thirds of patients with CID and low T-cell counts, such as those with autosomal recessive DOCK8 deficiency, display CMC [21, 22] . Those with CID and impaired T-cell function, caused by autosomal recessive T cell receptor (TCR)-a, autosomal recessive calcium release-activated calcium modulator 1 (CRACM1), autosomal recessive macrophage stimulating 1 / serine/threonine-protein kinase 4 (MST1/STK4), autosomal recessive regulatory factor X-associated ankyrin-containing protein (RFXANK) or autosomal recessive CD25 deficiencies, for example, have also been reported to display susceptibility to CMC [19, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] .
In other PIDs, CMC is one of the main clinical presentations [15,16 & ]. Approximately 85% of patients with autosomal dominant signal transducer and activator of transcription (STAT)3 deficiency and hyper-IgE syndrome (autosomal dominant HIES) display CMC in addition to severe staphylococcal skin and pulmonary disease [26,32-35,36 & ], with 64% of these patients displaying oral candidiasis from the neonatal period onwards. CMC has also been reported in 25% of patients with autosomal recessive interleukin-12Rb1 or interleukin-12p40 deficiency, both of which are genetic etiologies of Mendelian susceptibility to mycobacterial disease (MSMD) [37, 38] . Six of the seven patients reported in one large consanguineous multiplex kindred with autosomal recessive CARD9 deficiency displayed
KEY POINTS
CMC diagnosis should lead to the exploration of interleukin-17 immunity defects, such as STAT1 gain of function mutations in particular.
Candida CNS infection diagnosis should lead to explorations of possible chronic granulomatous disease or CARD9 deficiency.
, [39] [40] [41] [42] [43] [44] [45] [46] . This deficit probably results from impaired STAT3-dependent signaling downstream from interleukin-6, interleukin-21 and interleukin-23, impaired interleukin-12Rb1-dependent signaling downstream from interleukin-23 or impaired CARD9-dependent signaling downstream from C-type lectin receptors (CLRs), respectively, these signaling pathways being involved in interleukin-17 T-cell development and maintenance [47, 48] . Finally, in autosomal recessive autoimmune polyendocrinopathy syndrome type 1 [APS-1 or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)], caused by autoimmune regulator (AIRE) deficiency [49] [50] [51] and resulting in impaired T-cell tolerance, 88% of patients develop CMC at a mean age of 3.7 years [52] . High levels of neutralizing autoantibodies against interleukin-17A, interleukin-17F and/or interleukin-22 have been detected in the sera of APS-1 patients [41, 52] . Overall, these studies strongly suggest that human interleukin-17 immunity plays a critical role in defense against CMC [15- ,57], and they paved the way for the identification of the first genetic etiologies of CMCD [7] .
CMCD is defined as CMC in patients with no other prominent clinical signs and with none of the genetic defects mentioned above. Complete autosomal recessive interleukin-17RA and partial autosomal dominant interleukin-17F deficiencies, resulting in impaired interleukin-17 immunity, were first reported in one CMCD family each [58] . Subsequently, genome-wide approaches led to the discovery of heterozygous STAT1 missense mutations in patients with CMCD [59, 60] . These mutations, unlike the previously reported monoallelic or biallelic STAT1 loss-of-function mutations associated with susceptibility to mycobacterial, intracellular bacterial and viral infections [61, 62, 63 & ], were shown to be GOF. Almost 100 patients with STAT1 GOF mutations have been reported to date [59, 60, 64, 65 & , [66] [67] [68] [69] [70] [71] [72] . These patients developed CMCD at a mean age of 1.4 years, mostly affecting the oropharynx (98%), nails (58%), skin (46%) and esophagus (20%). CMCD-causing STAT1 mutations increase STAT1 responses to IFN-a/b, IFN-g and interleukin-27, which repress interleukin-17 T-cell development, probably accounting for the small numbers of interleukin-17-producing T cells in these patients and the resulting CMCD [59] . Accordingly, granulocyte-macrophage colony-stimulating factor (GM-CSF), followed by granulocyte colonystimulating factor (G-CSF) treatment, in one of these patients improved candidiasis and resulted, in parallel, in the restoration of normal interleukin17-producing T-cell counts and an increase in STAT3 levels [73 & ], confirming the role of interleukin-17 cytokines in mucosal cutaneous immunity to Candida infections. PIDs associated with CMC are summarized in Table 1 
PRIMARY IMMUNODEFICIENCIES UNDERLYING INVASIVE ASPERGILLOSIS
Aspergillus spp. are present in soils and decaying plant material. Spores are inhaled, and hyphae can grow in the lungs, leading to pulmonary aspergillosis, the most frequent (90%) clinical presentation. Invasive aspergillosis is a life-threatening disease with an incidence of 0.27/10 3 admissions and a global mortality rate at 3 months close to 45% [5] . The underlying diseases are mostly hematological malignancies and particularly acute myeloblastic leukemia (78%), with prolonged neutropenia, solid organ transplant, solid tumors, systemic inflammatory diseases and chronic respiratory diseases [5] . The prevalence of invasive aspergillosis is particularly high in patients with chronic granulomatous disease (CGD), 17% of whom develop invasive aspergillosis. A. fumigatus is the Aspergillus spp. most frequently associated with disease, and is found in approximately 40% of the CGD cases [85, 86] . A nidulans, which is encountered almost exclusively in CGD patients, is associated with a high mortality rate [87] . Invasive aspergillosis is mostly pulmonary in CGD patients [85, 86] . This disease results from an NADPH oxidase complex defect in phagocytes, mostly due to X-linked (CYBB) mutations [88] or biallelic mutations in autosomal (NCF1, NCF2, NCF4, CYBA) genes [54,55
& , 85, 86, [89] [90] [91] [92] [93] [94] . Tissue susceptibility to bacteria and fungi is because of a defect in reactive oxygen species production by phagocytes, resulting in an inability to kill microorganisms. Studies of patients with mycobacterial but not fungal disease and CYBB mutations impairing the respiratory burst in macrophages but not in monocytes or granulocytes [88] have suggested that disruption of the respiratory burst in granulocytes and monocytes underlies pulmonary aspergillosis in CGD patients.
Approximately 20% of autosomal dominant HIES patients develop invasive aspergillosis, always secondary to lung lesions (pneumatocyst formation or bronchiectasis), with 17% mortality [36 & ,95] . Autosomal dominant HIES patients display a normal inhibition of A. fumigatus growth by phagocytosis, unlike CGD patients [95] . The susceptibility of autosomal dominant HIES patients to IFD therefore results from the presence of pneumatocysts because of repeated bacterial infections of the lungs and defective STAT3-dependent epithelial immunity [95] . The incidence of invasive [97, 98] . Consistently with the role of GATA2 as a transcription factor involved in hematopoiesis and maintenance of the stem cell compartment, patients with GATA2 deficiency present a complex phenotype, with monocytopenia, B and Natural killer (NK) lymphopenia, low counts of dendritic cells and myelodysplasia [96, 97, [99] [100] [101] . Finally, invasive aspergillosis has been reported in rare cases of autosomal dominant or autosomal recessive severe congenital neutropenia (SCN) [102] [103] [104] [105] [106] or autosomal recessive type I leukocyte adhesion deficiency (CD18 deficiency) [107] [108] [109] .
PRIMARY IMMUNODEFICIENCIES UNDERLYING INVASIVE CANDIDIASIS
Candida spp. also causes candidiasis, the most frequent presentation of which is fungemia [110] . Candidemia is the fourth most important cause of nosocomial blood stream infection [111, 112] and the most frequent IFD in Western countries [113] , with a mortality rate of 40% [110] . Candidiasis is classically described in neutropenic patients, intensive care unit patients with catheters, treated with broad-spectrum antibiotics and with parenteral nutrition. Invasive candidiasis has occasionally been reported in patients with PIDs: 2% (n ¼ 486) of the patients from the French SCN registry developed invasive candidiasis, for example [109] . Despite the scarcity of data, autosomal recessive type 1 leukocyte adhesion deficiency with CD18 deficiency is also known to be complicated with invasive candidiasis [108] . Candida spp. infection of the central nervous system (CNS) is mostly reported after neurosurgery or in premature infants [114, 115] . It has also been reported in CGD patients [92] and, recently, in patients with autosomal recessive CARD9 deficiency. So far, at least three (probably four -three from an Iranian kindred and one of Korean origin) individuals have developed Candida infections of the CNS, at a mean age of 13 years [39, 79 && ], with Candida spp. meningoencephalitis reported in three cases. CARD9 is an adaptor molecule expressed in myeloid cells downstream from the CLRs Dectin-1, Dectin-2 and macrophageinducible C-type lectin [116 & ,117-123] , which recognize fungal pathogen-associated molecular patterns [94, 124, 125] . After coil-coiled domain phosphorylation by protein kinase C (PKC)-d [126] , activated CARD9 couples with B-cell lymphoma/leukemia (BCL)10 and mucosa-associated lymphoid tissue lymphoma translocation protein (MALT)1, resulting in NF-kB activation, leading to the secretion of proinflammatory cytokines [126] [127] [128] [129] . CARD9-deficient peripheral blood mononuclear cells (PBMCs) contain a smaller than normal proportion of interleukin-17 T cells, but the role of interleukin-17 immunity in human defense against Candida invasive infection remains unclear [39] .
&&
]. The preferential CNS location of Candida infection in CARD9-deficient patients may also result from the inability of monocytes, macrophages and/or microglial cells to eliminate Candida efficiently at the blood brain barrier [54] .
PRIMARY IMMUNODEFICIENCIES UNDERLYING DEEP DERMATOPHYTOSIS
Dermatophytes are cosmopolite filamentous fungi that frequently cause benign infections, such as tinea capitis, tinea corporis and/or onychomycosis [130] . By contrast, deep dermatophytosis is a rare condition defined by the invasion of the dermis and hypodermis by dermatophytes, sometimes associated with lymph node, brain, digestive tract or bone involvement [131, 132] . Deep dermatophytosis has been reported in immunocompromised patients with HIV infection (n ¼ 3) or on immunosuppressive therapy (n ¼ 16) [133] . Sixty-nine cases have been reported in patients without known immunodeficiency [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] , 45 of whom originated from North Africa. Twenty-four of these patients were from consanguineous families, with 19 familial cases from eight multiplex families. This strongly suggests that predisposition to idiopathic deep dermatophytosis is inherited as an autosomal recessive trait. Recently, 17 patients from eight kindreds with idiopathic deep dermatophytosis from North Africa (11 previously reported [134, [144] [145] [146] [147] [148] ]. These data provided evidence for a role of CARD9 in antifungal defense against dermatophytes, broadening the spectrum of IFDs associated with CARD9 deficiency. However, the underlying mechanism remains to be elucidated.
PRIMARY IMMUNODEFICIENCIES UNDERLYING DIMORPHIC FUNGAL INFECTIONS (ENDEMIC MYCOSES)
Dimorphic fungi are present as hyphae in the environment and as yeasts in tissues, the transition between these two forms being triggered by temperature changes. They have a limited geographic distribution. Coccidioides immitis or posadii is endemic to the South West United States, Paracoccidioides brasiliensis is endemic to Latin America and Histoplasmosma capsulatum is endemic to the Midwestern United States [149, 150] . Infection occurs by spore inhalation. Disseminated histoplasmosis occurs in patients with immunodeficiency, mostly AIDS, and involves the lymph nodes, liver, spleen, mucosae, bone marrow and brain [151] . Disseminated coccidioidomycosis involves the lungs, CNS and bones and occurs in patients without known risk factors in 55% of cases [152] . Patients with mutations affecting the interleukin-12/IFN-g circuit and MSMD [37] have been reported with dimorphic fungal infections. Indeed, interleukin-12Rb1-deficient patients from Arizona, India and Brazil with coccidioidomycosis (n ¼ 2), histoplasmosis (n ¼ 1) and paracoccidioidomycosis (n ¼ 1) have been reported [37, 153, 154] . Similarly, two IFN-gR1-deficient patients, one from Arizona and one from Texas, with disseminated coccidioidomycosis and histoplasmosis, respectively, have been described [155, 156] . Salmonellosis and mycobacterial infections were associated with these infections in all but one patient. Patients with disseminated dimorphic infections should therefore be explored for defects of the IFN-g/interleukin-12 circuit and patients with deficiencies in the IFN-g/ interleukin-12 axis should be considered at risk of infection with endemic fungi. Five patients with heterozygous STAT1 GOF mutations have recently been reported, two with disseminated coccidioidomycosis and three with histoplasmosis [65 & ]. Endemic mycosis occurred in these patients at a mean age of 13 years. Finally, disseminated histoplasmosis has also been reported in patients with autosomal dominant GATA2 deficiency [96, 98] , autosomal recessive DOCK8 deficiency [25] , idiopathic CD4 lymphopenia [157] [158] [159] [160] , and X-linked CD40L deficiency [161, 162] .
PRIMARY IMMUNODEFICIENCIES UNDERLYING CRYPTOCOCCOSIS
Cryptococcosis is a fungal infection mostly caused by the encapsulated yeast Cryptococcus neoformans. The burden of cryptococcosis is high: one million cases are reported each year in Sub-Saharan Africa, with more than 600 000 deaths/year in HIV-infected patients, in whom such infections are the fourth leading cause of death [163] . C. neoformans is present in the soil. The major route of infection is probably inhalation. The main clinical presentation for C. neoformans infections is meningoencephalitis (90% in HIV-positive and 70% in HIV-negative individuals) [164] . Other risk factors include solid organ transplantation, hematological malignancies, diabetes mellitus, cirrhosis, sarcoidosis, CD4 T-cell lymphopenia, prolonged corticosteroid or immunosuppressive treatment. Cryptococcosis has been reported in patients with idiopathic CD4 lymphopenia [165, 166] , with autosomal dominant GATA2 deficiency [96] , and in a few patients with X-linked CD40L deficiency [167, 168] . In addition, cryptococcosis was found in eight patients with neutralizing autoantibodies against IFN-g [169] and seven patients with neutralizing autoantibodies against GM-CSF [170 & ]. These data suggest, in addition to CD4
þ T cells, a role for GM-CSF and IFN-g in defenses against cryptococcosis, at the level of pulmonary macrophages. In patients of East Asian descent with disseminated nontuberculous mycobacterial infections, a genetic origin has recently been demonstrated for the presence of autoantibodies against IFN-g [171, 172] . Genetic defects of the IFN-g and/or GM-CSF signaling pathways may, therefore, create a predisposition to cryptococcosis. No genetic cause has yet been identified in patients with unexplained and isolated cryptococcosis.
PRIMARY IMMUNODEFICIENCIES UNDERLYING PNEUMOCYSTIS JIROVECII PNEUMONIA
Pneumocystis jirovecii is an obligate extracellular fungus [173] . Pneumocystis spp. are host-specific and P. jirovecii is an exclusively human pathogen [174, 175] . This fungus is ubiquitous and seroconversion occurs early in life. P. jirovecii is transmitted from individual to individual, through the air. It causes a severe form of interstitial pneumonia in patients with acquired or inherited immunodeficiencies (IDs). Pneumocystosis was the first infection reported in patients with AIDS in the United States, in 1981 [176, 177] . Pneumocystis pneumonia remains one of the leading causes of mortality and morbidity in AIDS patients [178] , and develops when CD4 þ T-cell count falls below CD40L, X-linked [167, 168] 200 cells/ml [177] . P. jirovecii pneumonia is also frequent in patients with SCID, and in patients with idiopathic CD4 lymphopenia [31, 157, 166] , demonstrating the crucial role of CD4 T cells. Patients with impaired NF-kB signaling, autosomal dominant IkB-a GOF mutations [19, 20] and X-linked NF-kB Essential Modulator (NEMO) deficiency [19] , autosomal recessive MHC class II deficiency [179] , autosomal recessive DOCK8 deficiency, X-linked Wiskott-Aldrich syndrome, and autosomal recessive CARD11 deficiency [25, [180] [181] [182] [183] [184] also develop pneumocystosis. Finally, P. jirovecii pneumonia is common in patients with X-linked CD40L deficiency, associated with recurrent bacterial and cryptosporidium infections. In a series of 79 X-linked hyper IgM (XHIGM) patients, 48% developed P. jirovecii pneumonia at a median age of 1.26 years, and this infection was often the revelatory symptom for XHIGM diagnosis [167] . XHIGM is caused by mutations of CD40L, encoding the CD40 ligand, which is expressed on T cells and necessary for cooperation between T and B lymphocytes and immunoglobulin class switch. Affected patients therefore have deficiencies of IgG, IgA and IgE and high levels of IgM antibodies. CD40L is also required for the maturation of antigen-presenting cells, the stimulation of macrophage effector functions and the antigen priming of T lymphocytes [167] . The T-cell defect is probably the main cause of pneumocystosis in this PID. PIDs associated with IFDs are summarized in Table 2 Table 3 .
CONCLUSION
If the last few years are anything to go by, the near future will bear witness to the discovery of single-gene inborn errors of immunity underlying fungal infections. Progress in this area will be facilitated by technological progress, in deep sequencing in particular, making it possible to decipher genetic etiologies of infectious diseases, including IFDs in particular. The genetic dissection of both superficial and invasive fungal infections should progressively lead to elucidation of the molecular and cellular mechanisms underlying protective immunity to fungal pathogens. Genetic dissection of the pathogenesis of inherited IFD will shed new light on the pathogenesis of IFD in other settings. The further genetic dissection of patients with no known risk factor displaying IFD should lead to the identification of new genetic causes of IFD. These discoveries will improve our knowledge of human antifungal immunity and should pave the way for the development of new, more appropriate treatments. 
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